Ipsen inks $137M cancer drug deal; Agios shares rocket up as presentation looms;

@FierceBiotech: Michigan investigators zero in on a new approach to a Notch cancer drug. FierceBiotechResearch story | Follow @FierceBiotech

@JohnCFierce: Following pioneering approval, Versant bankrolls next-gen oncolytics player Turnstone. Article | Follow @JohnCFierce

@DamianFierce: $MGNX gets the last laugh by misspelling "Servier" in its breakup announcement. Release | Follow @DamianFierce

> France's Ipsen has struck a deal to in-license development and commercialization rights to Montreal-based Telesta Therapeutics' MCNA for non-muscle invasive bladder cancer. Ipsen gains all rights outside of the United States, where Telesta is setting up commercial ops, Canada, South Africa, South Korea, Japan and Mexico. Telesta earns a $10 million upfront, up to $127 million in milestones and double-digit royalties. Release

> Shares of Agios ($AGIO) shot up 24% on Tuesday after the biotech announced that it plans to release new data on AG-120 in about a week. Release

Medical Device News

@FierceMedDev: NEA backs cancer genome Dx startup Personal Genome in $21M+ Series A. More | Follow @FierceMedDev

@VarunSaxena2: ICYMI: J&J device heads say the new med tech innovation model calls for more external partnerships. Story | Follow @VarunSaxena2

@EmilyWFierce: "Leadership is about creating futures that are not a direct path." - @broadinstitute's COO Samantha Singer. More/Feature | Follow @EmilyWFierce

> J&J's Ethicon partners with Fogarty Institute to back next-gen device innovation. Report

> Medtronic touts studies of its devices to monitor patients following sedation. Story

> Cleveland Clinic, Candescent Health partner to create cloud-based radiology network. More

Pharma News

@FiercePharma: Amgen's T-Vec wins FDA nod, EU committee recommendation. FierceVaccines story | Follow @FiercePharma

@EricPFierce: GSK says it 'takes seriously' issues at China plant that led UK regulators to pull GMP cert. More from FiercePharmaManufacturing | Follow @EricPFierce

@CarlyHFierce: Pfizer blows past sales forecasts, thanks to overachievers Prevnar, Ibrance. Story | Follow @CarlyHFierce

> Express Scripts: AbbVie hep C meds still available for the right patients. News

> Valeant draws more fire for tapping insiders to investigate fraud allegations. More

> Gilead faces Q3 slowdown for hep C superstars. Story

Biotech Research News

> JAK inhibitors demonstrate fresh promise in restoring hair growth. Report

> Restoring testosterone production may be safer than replacement treatments. Item

> Howard Hughes researcher IDs a new target for autoimmune disease. More

> Michigan investigators zero in on a new approach to a Notch cancer drug. Story

> Drug-device combo from Wyss takes a new approach on treating stroke. Article

Pharma Marketing News

> Shire nabs much-needed PhIII boost for dry-eye prospect lifitegrast. Item

> Merck says it won't need AbbVie-sized discounts to win in hep C. Article

> With competition heating up, Pfizer may drop psoriasis effort on Xeljanz. Report

> Merck's Keytruda has a shot at a bigger share of NSCLC sales. Story

> No exodus from DPP-4s on Jardiance CV data, but SGLT2 scripts are shifting: Merck. More

Vaccines News

> GSK's malaria vaccine hits roadblock as WHO recommends pilot projects. News

> Pfizer continues vaccines hot streak with 43% Q3 growth. Report

> Amgen's T-Vec wins FDA nod, EU committee recommendation. Story

> GSK reports PhIII success for shingles jab, will file for approval in late 2016. Article

> SciVac Therapeutics agrees to acquire VBI Vaccines. Item

Suggested Articles

Reata’s bardoxolone improved kidney function in a phase 3 trial of patients with a rare form of chronic kidney disease.

The suit alleges the FDA imposed the hold “without notice or explanation” and has since “rebuffed” Regenxbio’s repeated requests for an explanation.

Bolt Biotherapeutics presented positive results from animal trials of its lead drug, a tumor-targeting antibody connected to an immune stimulator.